CA 19-9

A tumour-associated carbohydrate antigen located on the sialylated Lewis A blood group antigen (individuals who are genotypically Lewis a-b-[Lea-b-] comprise 5% of the population and cannot synthesize the antigen).

Serum levels
> 37 U/mL occur in 72–100% of patients with pancreatic cancer; 97% of those with levels > 1000 U/m; 65% of those with hepatocellular carcinoma; 20+% of those with gastric cancer; 20% of those with colorectal cancer. Because CA19-9 is also elevated in benign conditions (e.g., obstructive jaundice, liver disease, acute and chronic pancreatitis, diabetes, interstitial lung disease, collagen vascular disease, cholecystitis and cirrhosis of the liver), it is not widely used as a cancer marker. At one time it was regarded as useful in differentiating mesothelioma (in which it is negative) from various adenocarcinomas (in which it is positive).

CA 19-9 (Cancer antigen 19-9)

A tumor marker associated with pancreatic cancer.

Mentioned in: Tumor Markers

Mentioned in

References in periodicals archive

- Combination of sTRA and CA19-9 Test to Detect Pancreatic Cancer Biomarkers

Biomarkers: Discovery Techniques and Applications - A Global Market Overview 2019

According to the company, the results demonstrated that the IMMray PanCan-d signature together with CA19-9 generated ROC AUC-values of 0.97, 0.98 and 0.96 when differentiating PDAC (pancreatic cancer) vs non-PDAC symptomatic individuals, healthy controls and type II diabetes, respectively.

Immunovia to present findings of IMMray PanCan-d optimisation study at PancreasFest 2019

In addition, the CA19-9 levels dropped 94% from levels prior to this line of therapy.

NewLink Genetics announces updated NLG802 results at immuno-oncology meeting

While the mean CA19-9 value before RT was 53.2[+ or -]115.4 (median, 16.1), it was 17.5[+ or -]32.1 (median, 7.0) in the 5th week after RT.

Are there predictors that can determine neoadjuvant treatment responses in rectal cancer?

Laboratory test results were as follows: CA125: 82 U/mL, CA19-9: 42 U/mL, and glycated hemoglobin (HbA1c): 11%.

Uterine giant cell carcinoma: a case report and review of the literature/Uterin dev hucreli karsinom: olgu sunumu ve literatur sunumu

During the preoperative period, the mean levels of CA 125, CEA, CA19-9 and CA 15-3 in all study patients were 63.19[+ or -]93.8 U/mL (range 3.09-394 U/mL), 31.29[+ or -]76.63 U/mL, 20.83[+ or -]11.24 U/mL (range 6.40-48.60 U/mL) and 2.32[+ or -]2.09 ng/mL (range 0.50-10.8 ng/mL), respectively.

RETROSPECTIVE ANALYSIS OF BORDERLINE OVARIAN TUMORS: OUTCOMES AT A SINGLE CENTER

Immunohistochemical staining were carried out on the cell block and core biopsy sections using antibodies to thyroid transcriptor factor-1 (TTF-1), Napsin-A, Thyroglobulin, CD10, PAX 8, AMACR, CA19-9 and CD57 (Automated Ventana Bench Mark machine, the EnVisionTm System).

Fine needle aspiration cytology of pulmonary papillary adeno-carcinoma mimicking papillary thyroid carcinoma

A CA19-9 level > 129 U/L in the setting of a biliary mass is highly suggestive of cholangiocarcinoma.

Perihilar cholangiocarcinoma

Tumor markers including Alpha Fetoprotein, CEA and CA19-9 were also normal.

PRIMARY NEUROENDOCRINE TUMOUR OF LIVER

In the case of CA19-9, this limited utility may reflect the fact that this biomarker is not expressed in some patients, and in others it may be increased for reasons unrelated to PDAC, such as biliary infections and inflammatory processes (6).

Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNAfrom Patients with Pancreatic Ductal Adenocarcinoma

Laboratory examination showed elevated carbohydrate antigen 125 (CA125) level, 280.7 IU/ml, and normal CA19-9 and carcinoembryonic antigen (CEA) level.

Primary uterine primitive neuroectodermal tumor